Literature DB >> 17760807

Dysregulation of CD47 and the ligands thrombospondin 1 and 2 in multiple myeloma.

Jannie M Rendtlew Danielsen1, Lene Meldgaard Knudsen, Inger Marie Dahl, Marianne Lodahl, Thomas Rasmussen.   

Abstract

CD47 and thrombospondin 1 and 2 (TSP1 and TSP2) expression were analysed by real-time reverse transcription polymerase chain reaction in fluorescence-activated cell sorted plasma cells (PCs) from patients at consecutive stages of multiple myeloma (MM) development. 80% of MM patients, but only 39% of patients with monoclonal gammopathy of undetermined significance (MGUS) expressed CD47; median expression level increased 10-fold with progression from MGUS to MM. Elevated TSP1/TSP2 levels occurred in bone marrow cultures from MM patients compared with healthy donors. CD47 and TSP1/TSP2 may have a potential role in the pathophysiology of MM, probably in the interaction between MM PCs and the microenvironment.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17760807     DOI: 10.1111/j.1365-2141.2007.06729.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  35 in total

Review 1.  The CD47-SIRPα pathway in cancer immune evasion and potential therapeutic implications.

Authors:  Mark P Chao; Irving L Weissman; Ravindra Majeti
Journal:  Curr Opin Immunol       Date:  2012-02-04       Impact factor: 7.486

2.  CD47 Blockade and Cowpea Mosaic Virus Nanoparticle In Situ Vaccination Triggers Phagocytosis and Tumor Killing.

Authors:  Chao Wang; Nicole F Steinmetz
Journal:  Adv Healthc Mater       Date:  2019-03-06       Impact factor: 9.933

3.  Dendritic Cells but Not Macrophages Sense Tumor Mitochondrial DNA for Cross-priming through Signal Regulatory Protein α Signaling.

Authors:  Meng Michelle Xu; Yang Pu; Dali Han; Yaoyao Shi; Xuezhi Cao; Hua Liang; Xiang Chen; Xiao-Dong Li; Liufu Deng; Zhijian J Chen; Ralph R Weichselbaum; Yang-Xin Fu
Journal:  Immunity       Date:  2017-08-08       Impact factor: 31.745

Review 4.  Thrombospondin-1 regulation of latent TGF-β activation: A therapeutic target for fibrotic disease.

Authors:  Joanne E Murphy-Ullrich; Mark J Suto
Journal:  Matrix Biol       Date:  2017-12-27       Impact factor: 11.583

5.  Dominant role of CD47-thrombospondin-1 interactions in myeloma-induced fusion of human dendritic cells: implications for bone disease.

Authors:  Anjli Kukreja; Soroosh Radfar; Ben-Hua Sun; Karl Insogna; Madhav V Dhodapkar
Journal:  Blood       Date:  2009-08-06       Impact factor: 22.113

6.  Therapeutic Targeting of CD47 to Modulate Tissue Responses to Ischemia and Radiation.

Authors:  David R Soto-Pantoja; Jeff S Isenberg; David D Roberts
Journal:  J Genet Syndr Gene Ther       Date:  2011-09-26

Review 7.  Programmed cell removal: a new obstacle in the road to developing cancer.

Authors:  Mark P Chao; Ravindra Majeti; Irving L Weissman
Journal:  Nat Rev Cancer       Date:  2011-12-08       Impact factor: 60.716

Review 8.  Therapeutic opportunities for targeting the ubiquitous cell surface receptor CD47.

Authors:  David R Soto-Pantoja; Erica V Stein; Natasha M Rogers; Maryam Sharifi-Sanjani; Jeffrey S Isenberg; David D Roberts
Journal:  Expert Opin Ther Targets       Date:  2012-10-27       Impact factor: 6.902

Review 9.  Matricellular proteins as regulators of cancer metastasis to bone.

Authors:  Timothy N Trotter; Yang Yang
Journal:  Matrix Biol       Date:  2016-01-22       Impact factor: 11.583

10.  Inhibition of Transforming Growth Factor-β Activation Diminishes Tumor Progression and Osteolytic Bone Disease in Mouse Models of Multiple Myeloma.

Authors:  Ailing Lu; Manuel A Pallero; Weiqi Lei; Huixian Hong; Yang Yang; Mark J Suto; Joanne E Murphy-Ullrich
Journal:  Am J Pathol       Date:  2016-01-20       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.